The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
04-Oct-23
$610 million
Target:
Lucky Bucks, LLC
Advised the Term Loan Ad Hoc Group to Lucky Bucks, one of the largest Class B coin operated amusement machine (“COAM”) route operators in Georgia, on Lucky Bucks’ financial restructuring and chapter 11 process.
27-Sep-23
Undisclosed
Target:
Slayback Pharma LLC
Acquiror:
Azurity Pharmaceuticals
Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products
30-Dec-22
$153 million
Target:
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Acquiror:
Mayne Pharma
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
19-Aug-22
$2.2 billion
Target:
GI Alliance
Acquiror:
Apollo Hybrid Value Fund
Advising the management and majority physician owners of GI Alliance, the largest gastroenterology practice in the United States, on its recapitalization and buyout of minority partner, Waud Capital
19-Feb-21
$33 million
Target:
Acacia Pharma Group plc
Acquiror:
N/A
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
09-Feb-21
Undisclosed
Target:
US Acute Care Solutions
Acquiror:
Apollo Hybrid Value Fund
Advising US Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on its recapitalization and buyout of minority partner, Welsh Carson
01-Oct-20
$1.05 billion
Target:
Akorn, Inc.
Acquiror:
First Lien Term Loan Lenders
Advised Ad Hoc Group of First Lien Term Loan Lenders on Akorn’s in-court recapitalization
02-Jul-20
$890 million
Target:
Brookfield Property Partners L.P.
Acquiror:
Brookfield Asset Management Inc.
Advised the Special Committee of Brookfield Property Partners L.P., one of the world’s premier commercial real estate companies, on its repurchase of up to $890 million of publicly held units, funded with an equity investment from Brookfield Asset Management and its affiliates
02-May-18
$3.7 billion
Target:
Concordia International Corp.
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
09-Jan-18
$3.1 billion
Target:
Pure Industrial Real Estate Trust
Acquiror:
Blackstone Property Partners
Advised the Special Committee of the Board of Trustees of Pure Industrial Real Estate Trust ("PIRET"), the largest pure-play industrial REIT in Canada, regarding the acquisition of PIRET by Blackstone Property Partners
06-Oct-17
$18.4 billion
Target:
Caesars Entertainment
Advised selected Second Lien Noteholders, including Canyon Capital Advisors, Mason Capital, Paulson & Co. and Soros Fund Management regarding Caesars Entertainment Operating Company’s Chapter 11 proceedings
20-Apr-17
$4.3 billion
Target:
Brookfield Canada Office Properties
Acquiror:
Brookfield Property Partners L.P.
Advised the Special Committee of Brookfield Canada Office Properties, Canada’s pre-eminent office real estate investment trust, on its go private transaction with Brookfield Property Partners L.P.
13-Oct-16
$NA
Target:
Concordia International Corp
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
08-Aug-16
$1.5 billion
Target:
Whistler Blackcomb Holdings Inc.
Acquiror:
Vail Resorts, Inc.
Advised Whistler Blackcomb Holdings Inc., a 75% owner and operator of the largest and most visited mountain resort in North America, on its sale to Vail Resorts, Inc.
01-Apr-13
$NA
Target:
Morgans Hotel Group
Advised the Special Transaction Committee of the Board of Morgans Hotel Group on the transfer of its ownership interests in Delano South Beach and The Light Group to The Yucaipa Companies in exchange for the cancellation of certain securities held by Yucaipa (debt, preferred stock and warrants) together with a $100 million rights offering backstopped by Yucaipa
07-Nov-11
$398 million
Target:
American Dental Partners, Inc.
Acquiror:
JLL Partners
Advised American Dental Partners, Inc. (NASD: ADPI), one of the nation’s leading business partners to dental group practices, on its sale to JLL Partners, a leading private equity firm
15-Dec-10
$12.9 billion
Target:
Alcon, Inc.
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
09-Nov-10
$27.0 billion
Target:
General Growth Properties Inc.
Advised the 2006 Credit Facility Lenders, the largest class of unsecured debt with claims in excess of $2.8 billion, in connection with the Chapter 11 proceedings of mall REIT GGP, which resulted in cash payoff of the facilities in full
10-Jun-10
$580 million
Target:
Tishman Speyer Washington D.C. Portfolio
Advised term loan and credit facility lenders to the Tishman Speyer partnership holding a portfolio of 28 office buildings in Washington D.C. and the surrounding area on a restructuring which resulted in payoff of the facilities in full
25-Jan-07
$3.3 billion
Target:
Cardinal Health, Inc., Pharmaceutical Technologies and Services division
Acquiror:
The Blackstone Group
Provided fairness opinion to the board of directors of Cardinal Health, Inc., a global company serving the health-care industry, on the sale of its Pharmaceutical Technologies and Services business, which provides outsourced services and proprietary technologies to the global pharmaceutical and biotechnology industries
10-Aug-06
$NA
Target:
Forest City Ratner
Acquiror:
Forest City Enterprises Inc.
Advised Forest City Enterprises, Inc. on the restructuring of its business relationship with its New York City affiliate Forest City Ratner
03-Aug-06
$6.0 billion
Target:
Reckson Associates Realty Corporation
Acquiror:
SL Green Realty Corporation
Advised the independent directors of Reckson, a real estate investment trust specializing in properties located in New York City and the surrounding Tri-State area, on the sale of Reckson to SL Green
29-Aug-04
$3.8 billion
Target:
LNR Property Corporation
Acquiror:
Cerberus Capital Management, L.P.
Advised the Special Committee of the Board of Directors and the Board of Directors of LNR Property Corporation, one of the US’ leading real estate investment, finance and management companies, on its sale to Cerberus Capital Management, L.P. and its real estate affiliate, Blackacre Institutional Capital Management, LLC